沐舒坦治疗慢性阻塞性肺疾病缓解期的的疗效观察.docVIP

沐舒坦治疗慢性阻塞性肺疾病缓解期的的疗效观察 　　[摘要] 目的:观察沐舒坦对慢性阻塞性肺疾病(COPD)缓解期患者的治疗效果。方法:60例COPD缓解期入选病例,随机分为观察组和对照组,观察组在对照组治疗的基础上加用沐舒坦口服,随访1年。于治疗前后临床问卷调查及体征检查评分,观察治疗期间病情急性加重次数。结果:治疗1年后观察组临床症状评分显著改善(P0.05),且治疗组治疗期间急性加重次数较对照组明显减少(P0.05)。结论:沐舒坦可改善COPD缓解期患者的临床症状并减少急性加重次数。 　　[关键词] 沐舒坦;慢性阻塞性肺疾病;临床疗效 　　[中图分类号] R563[文献标识码]B [文章编号]1673-7210(2010)06(c)-084-02 　　 　　Effects of Mucosolvin on stable chronic obstructive pulmonary disease 　　ZHAO Yali1, WANG Ailian2, LIUYun1 　　(1.The PeoplesHospital of Fuyong, Baoan Area, Shenzhen City, Guangdong Province, Shenzhen 518103, China; 2. The General Hospital for Workers of Fenxi Mining Group, Jiexiu 031200, China) 　　[Abstract] Objective: To observe the curative effects of Mucosolvin on patients with stable chronic obstructive pulmonary disease (COPD). Methods: 60 patients with stable COPD were divided into observation group and control group randomly. Patients in control group received conventional therapy and patients in observation group received both oral Mucosolvin and conventional therapy. Scores on the clinical symptom questionnaire, scores on physical sign checks and the frequencies of acute exacerbation were evaluated before and after one-year treatment. Results: There were significant difference of observation group after one-year treatment on scores on clinical symptom (P0.05). Compared with control group, the frequencies of acute exacerbation of observation group were reduced more significantly (P0.05). Conclusion: Mucosolvin can improve the clinical symptom and reduce the frequencies of acute exacerbation of patients with stable COPD. 　　[Key words] Mucosolvin; Chronic obstructive pulmonary disease; Clinical effct 　　 　　慢性阻塞性肺疾病(COPD)是一种具有气流受限特征的可以预防和治疗的疾病,气流受限不完全可逆、呈进行性发展,与肺部对香烟烟雾等有害气体或有害颗粒的异常炎症反应有关[1-2]。COPD患者的咳嗽多因痰多引起,且患者痰多、黏稠不易咳出,会影响通气功能,增加感染的机会。盐酸氨溴索(商品名:沐舒坦)是一种新型呼吸道润滑祛痰药,已广泛用于治疗呼吸系统疾病且疗效肯定。本研究对口服沐舒坦治疗COPD缓解期的临床疗效进行了观察,现将观察结果报道如下: 　　1 资料与方法 　　1.1 一般资料 　　60例COPD缓解期入选病例,均为我院2008年6月～2009年12月门诊随访患者,其中男44例,女16例,平均年龄(70±12)岁,病程5～23年。全部